New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free
Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Thursday, November 12, 2026

Back to the front page

Looking Back at Another Successful Thesis

DoubleU Games raised its all-cash tender offer for DoubleDown Interactive minority holders to $16.25 per ADS from $11.25 after net cash made the earlier bid untenable.

DDI $779M
The Value Road 3 clicks

From X

@convequity 1 click

Convequity on X

The neocloud debt pullback is about how long delivery takes, and the useful response is a targeted renegotiation that pays lenders for more time, not a liquidation of the borrowers. Demand for AI compute is huge, and investors were eager to fund the buildout. That demand is still there. What is drying up is debt for neoclouds that cannot show revenue outside AI data centers. In our view the pullback is almost entirely about timing. Compute gets billed only once the site is built, powered and staffed, long after the cash has gone in. That wait is the squeeze. As a hypothetical, if the neoclouds could stand compute up and start billing ten times faster, the problem would ease. They would be generating revenue and cash flow to fund more of the next investment themselves, and outside investors could ask less interest on future money. On the latest reported figures, $CRWV's operating cash flow is positive but its free cash flow is negative, because the build is still being paid for. Lenders are now pulling back from neoclouds that have no revenue outside AI data centers. The race between neoclouds pushed CoreWeave too far. They took the debt probably knowing the delivery timetable was tight, because a firm that is not aggressive enough ends up with no compute at all. If lenders call a default and CoreWeave is then bankrupted and liquidated, the credit investors are left holding the GPUs. Taking the collateral does not make it earn. Someone still has to power, staff and bill the site, so the lenders must find another company to run it. In our view they lose money net-net, the handover is costly, and the buildout stalls to a degree. Amazon, Microsoft and Google can keep funding GPUs from businesses that already earn. A stall on the independent side leaves more AI compute with them, which in our view is bad for an AI-led economy. Who would buy a failed neocloud is still open. Blanket leniency would be a moral-hazard problem. If every late project gets time for free, covenants stop binding and the next borrower takes the same risk again. The exception here is that the demand behind the loans is still there. A lender can give more time to a project that will cover its debt once it is billing, and be paid for the wait with a higher margin, a fee or upside. When the cash flow recovers, that is the lender's reward. Musk predicting that 200-plus neoclouds will fail or consolidate makes the pullback worse. More credit investors step back, and the wait gets longer for everyone still building.
@kevin__mak 6 clicks

Kevin Mak on X

$CMPS Great article this weekend in Politico about psychedelics. There's overwhelming alignment across the government to moving these treatments forward. Given this, I really can't see COMP360 getting ensnared in the approval process, or worse, through reimbursement/REMS bureaucracy once commercialized. At current prices, I believe the market is treating CMPS as a "risky proposition" because historically, that was very true. I think that regime has changed dramatically in the last 12 months. Spend some time talking to an LLM about COMP360 vs Spravato (>$2B/year in sales). Which would you rather take? But even more importantly, Spravato has <5% market share of Treatment Resistant Depression, the other ~95% of patients are generally seeking options. Disclosure: Creek Drive and its affiliated funds holds a long position in CMPS. Views expressed are current opinions for information only, subject to change and are not investment advice or a recommendation to buy or sell any security. Investing involves the risk of loss and past performance is not indicative of future performance. See the disclosures link in my bio for more important information. --- The VA has led the push in Washington to advance access to psychedelic therapy. It’s involved in 20 psychedelic clinical trials and was one of the first major health care systems to roll out Spravato, an FDA-approved treatment for depression using esketamine, a chemical component found in ketamine. Ketamine — an anesthetic frequently referred to as a psychedelic due to its psychoactive effects — is currently the only psychedelic-like drug approved for medical use. Trump administration officials say they hope more will be approved soon. “We want to see the drug approved if it’s safe and effective, and the reason why is because there’s a mental health crisis,” Matt Zorn, deputy general counsel at the Health and Human Services Department, told POLITICO.
@aleabitoreddit 6 clicks

Serenity on X

Just another $40B going into the "AI Infra" Bubble... Elon stated this $SPCX financing would primarily fund $NVDA GPU procurement H1 2027. Which indirectly increases demand for memory, networking, etc needed. In some other notes, VPEC today in UDN: "InP substrates is seriously in short supply" in regards to suppliers like $AXTI. - Morgan Stanley believes that InP substrates, EML and CW lasers will be the primary bottlenecks - VPEC emphasized that whoever can secure more raw material supply in the future will have greater pricing power and influence in the market. Very true about supply procurement... both upstream materials like epiwafers/substrates to ultimately compute. We're in a volatile period where all your largest companies in the world are fighting over control of the future of AI infrastructure. Any slowdown seems unlikely.

Investor Letters

All letters

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

QURE $1.7B
Triple S Special Situations Investing 2 clicks

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

FG $3.2B
Mispriced Assets 3 clicks

Top Rebound Stocks for Nov’26

Texas Pacific Land's 50% selloff reflects faded data-center expectations, while its Permian royalty business generated $498 million of 2025…

TPL $19B
Rebound Capital 2 clicks

Peloton: Beyond The Bike

Peloton’s connected-fitness subscribers fell 9% year over year to 2.475 million, with another high-single-digit holiday decline forecast as…

PTON $2.6B
TSOH Investment Research 3 clicks
MONOY · long

Monotaro CO LTD

MonotaRO, traded as MONOY in the U.S. and 3064 in Japan, is a Japanese MRO distributor recommended as a long.

MONOY $7.4B
Value Investors Club

DoorDash’s FBA Moment

DoorDash’s $17 billion Instacart deal targets DashMart warehouse scale, where 99%+ order accuracy and faster delivery address the limits of…

DASH $78BKR $41B
MBI Deep Dives 3 clicks

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

YouTube 4

Blogs 15

Seeking Alpha 84 of 286

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

91 accounts
Nominate an account

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.